Consilium MedicumConsilium Medicum2075-17532542-2170Consilium Medicum94858Review ArticleBladder capacity and detrusor fibrosis as factors predicting the clinical course of the painful bladder/interstitial cystitis syndromeZaytsevA. Vnauch.ot@mail.ruTsybulyaO. A-KovylinaM. V-IbragimovA. A-PushkarD. Yu-A.I.Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Health of the Russian Federation15072017197606428122021Copyright © 2017, Consilium Medicum2017Painful bladder syndrome / interstitial cystitis is a progressive disease of the bladder, leading to loss of its capacity and severe pelvic pain. Etiology remains unclear, one of the reasons is the violation of the integrity and permeability of the glycosaminoglycan layer of the urothelium due to circulatory disorders. Treatment remains empirical and multidomain. In connection with the development of detrusor fibrosis in complex therapy in the early stages of the disease should include drugs with antifibrotic action, for example, Longidaze.painful bladder syndrome/interstitial cystitisdetrusor fibrosisfibrogenesisLongidazeefficacyсиндром болезненного мочевого пузыря/интерстициальный циститфиброз детрузорафиброгенезЛонгидазаэффективность[Van de Merwe J.P, Nordling J, Bouchelouche P et al. Diagnostic criteria, classification, and nomenclature for painful bladder syndrome/interstitial cystitis: an ESSIC proposal. Eur Urol 2008; 53: 60-7.][Sant G.R, Kempuraj D, Marchand J.E, Theoharides T.C. The mast cell in interstitial cystitis: role in pathophysiology and pathogenesis. Urology 2007; 69 (Suppl. 4): 34-40.][Forrest J.B, Moldwin R. Diagnostic options for early identification and management of interstitial cystitis/painful bladder syndrome. Int J Clin Pract 2008; 62: 1926-34.][Richter B, Hesse U, Hansen A.B et al. Bladder pain syndrome/interstitial cystitis in a Danish population: a study using the 2008 criteria of the European Society for the Study of Interstitial Cystitis. BJU Int 2010; 105: 660-7.][Bigg H.F, Wait R, Rowan A.D, Cawston T.E. The mammalian chitinase - like lectin, YKL-40, binds specifically to type I collagen and modulates the rate of type I collagen fibril formation. J Biol Chem 2006; 281: 21082-95.][Johansen J.S. Studies on serum YKL-40 as a biomarker in diseases with inflammation, tissue remodelling, fibroses and cancer. Dan Med Bull 2006; 53: 172-209.][Letuve S, Kozhich A, Arouche N et al. YKL-40 is elevated in patients with chronic obstructive pulmonary disease and activates alveolar macrophages. J Immunol 2008; 181: 5167-73.][Richter B et al. YKL-40 and mast cells are associated with detrusor fibrosis in patients diagnosed with bladder pain syndrome/interstitial cystitis according to the 2008 criteria of the European Society for the Study of Interstitial Cystitis. Histopathology 2010; 57: 371-83. DOI: 10.1111/j.1365-2559.2010.03640][Walker S.J, Zambon J, Andersson K.E et al. Bladder Capacity is a Biomarker for a Bladder Centric versus Systemic Manifestation in Interstitial Cystitis/Bladder Pain Syndrome. J Urol 2017. pii: S0022-5347(17)30230-6. DOI: 10.1016/j.juro.2017.02.022. [Epub ahead of print.]][Зайцев А.В., Пушкарь Д.Ю., Корсунская И.Л. и др. Современные аспекты диагностики и лечения синдрома болезненного мочевого пузыря/интерстициального цистита. РМЖ. 2010; 18 (381): 1084-9.][Пушкарь Д.Ю., Зайцев А.В., Ковылина М.В. и др. Гистоморфология уротелия при воспалительных заболеваниях мочевого пузыря. Вестн. ВолГМУ, 2011; 2: 94-7.][Пушкарь Д.Ю., Зайцев А.В. Лонгидаза в лечении больных интерстициальным циститом. Урология. 2007; 5: 35-7.][Ковылина М.В., Зайцев А.В., Ибрагимов Р.А., Корсунская И.Л. Роль ферментных препаратов в комплексном лечении больных с синдромом болезненного мочевого пузыря/интерстициальным циститом. Эффективная фармакотерапия. 2013; 16: 8-12.][WHO Drug Information 2015; 29: 3.]